Cited by 79Attention Deficit Hyperactivity DisorderDevelopmental and Educational NeuropsychologySchizophrenia research and treatment

Effects of Stimulant Medication on Neuropsychological Functioning in Young Adults With Attention-Deficit/Hyperactivity Disorder

Open access
Biederman, Joseph, Seidman, Larry J., Petty, Carter R., Fried, Ronna, Doyle, Alysa E., Cohen, Daniel R., Kenealy, Deborah C., Faraone, Stephen V.·2008·The Journal of Clinical Psychiatry

Abstract

OBJECTIVE: The main goal of this study was to evaluate the impact of stimulant medication on executive function deficits in a group of adolescents and young adults with attention-deficit/hyperactivity disorder (ADHD; DSM-III-R criteria). METHOD: Male and female subjects aged 15 to 25 years were divided into 3 groups: subjects with ADHD treated with stimulants who took their medication at the time of testing (ADHD active stimulant treatment: N = 26), subjects with ADHD who had not taken stimulant medication in the past month (ADHD no stimulant treatment: N = 94), and non-ADHD control subjects (controls: N = 133). The neuropsychological battery assessed domains of cognitive functioning known to be relevant in ADHD, including tests of executive functions and learning and memory. Data were collected from July 1998 to April 2003. RESULTS: The ADHD no stimulant treatment group had significantly lower aggregate scores compared with the controls for the total aggregate, working memory, interference control, processing speed, sustained attention, and verbal learning domains (all p < .001). The ADHD active stimulant treatment group had significantly poorer scores on the total aggregate (p = .002), interference control (p < .001), and processing speed (p = .003) domains compared with the controls. The ADHD active stimulant treatment subjects scored significantly higher on the domains of sustained attention (p = .04) and verbal learning (p = .03) compared with the ADHD no stimulant treatment subjects. CONCLUSIONS: Our study showed that subjects with ADHD who took stimulant medication had higher neuropsychological measures of attention compared with subjects with ADHD who did not take stimulant medication, but differences were not found for other measures of executive function.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4088/jcp.v69n0715

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Stimulants and atomoxetine yield modest improvements in behavioural measures of executive functioning as well as performance on executive memory, reaction time and inhibitory control tasks.

    “stimulants 187 and atomoxetine 188 yield modest improvements in behavioural measures of executive functioning as well as performance on executive memory, reaction time and inhibitory control tasks 72 .”

    From Attention-deficit/hyperactivity disorder (2015) · cites this paper as [187]

    The Results (page unavailable) report modestly higher sustained-attention and verbal-learning scores in adolescents and young adults with ADHD taking stimulants. The Discussion (page unavailable) says stimulants did not affect interference control or processing speed, so this paper does not support the attributed improvements in inhibitory control and reaction-time-related performance. It does not assess atomoxetine, which has a separate citation in the citing sentence. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Other stimulant ADHD medications that affect norepinephrine and dopamine levels, such as methylphenidate, have also shown efficacy for improving deficits in some executive functioning categories but not others.

    “Other stimulant ADHD medications that affect norepinephrine and dopamine levels, such as methylphenidate, have also shown efficacy for improving deficits in some executive functioning categories but not others [30], [31].”

    From Atomoxetine Effects on Executive Function as Measured by the BRIEF-A in Young Adults with ADHD: A Randomized, Double-Blind, Placebo-Controlled Study (2014) · cites this paper as [30]

    The Results (page not specified) report better sustained attention and verbal learning scores among participants taking stimulants, but not improvements across other measured executive-function domains. The paper studies stimulants as a group; our copy does not establish a methylphenidate-specific effect or discuss norepinephrine and dopamine levels. Its findings therefore support the uneven pattern of improvement, but not those drug-specific details. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • In the same study, the ADHD subgroup on medication had better performance on sustained attention (CPT) and verbal learning (California Verbal Learning Test) than the ADHD subgroup not on medication.

    “A comparison of ADHD subgroups revealed that the subgroup on medication had better performance on sustained attention (measured by the CPT) and verbal learning (measured by the California Verbal Learning Test).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 5

  1. [6]6. Biederman J, Monuteaux M, Seidman L, et al. Impact of executive function deficits and ADHD on academic outcomes in children. J Consult Clin Psychol 2004;72:757-766
  2. [7]7. Faraone SV, Biederman J, Kiely K. Cognitive functioning, learning disability, and school failure in attention-deficit/hyperactivity disorder: a family study perspective. In: Beitchman J, ed. Language, Learning and Behavior Disorders. Essex, England: Cambridge University Press; 1996:247-271
  3. [20]20. Willcutt EG, Doyle AE, Nigg JT, et al. Validity of the executive func- tion theory of ADHD: a meta-analytic review. Biol Psychiatry 2005; 57:1336-1346
  4. [24]24. Rey A. L'examen psychologique dans les cas d'encephalopathie traumatique. Les Archives de Psychologie 1941;28:286-340
  5. [34]34. Bouffard R, Hechtman L, Minde K, et al. The efficacy of 2 different FOCUS ON CHILDHOOD AND ADOLESCENT MENTAL HEALTH PSYCHIATRIST.COM dosages of methylphenidate in treating adults with attention-deficit/ hyperactivity disorder. Can J Psychiatry 2003;48:546-554

Cited by

Sorted by citations

Authors
Biederman, J., Seidman, L. J., Petty, C. R., Fried, R., Doyle, A. E., Cohen, D. R., Kenealy, D. C., & Faraone, S. V.
Affiliations
  • Massachusetts General Hospital (US)
  • SUNY Upstate Medical University (US)
Venue
The Journal of Clinical Psychiatry
Published
2008-07-15
Volume
69
Issue
7
Pages
1150-1156
ISSN
0160-6689 (ISSN-L)
OpenAlex
W1991127706
Cited by
79
References
36
Citations by year
2025: 4 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 4 · 2020: 2 · 2018: 3 · 2017: 3 · 2016: 4 · 2015: 9 · 2014: 10 · 2013: 8 · 2012: 10
FWCI
3.98
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • National Alliance for Research on Schizophrenia and Depression
  • U.S. Public Health Service
  • National Institute of Mental Health
  • National Institute of Child Health and Human Development
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD036317, 5 R01 HD36317-07)
  • UCB Pharma
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Social Sciences › Psychology › Neuropsychology and Physiological Psychology › Developmental and Educational Neuropsychology
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
attention deficit hyperactivity disorder, stimulant medication, executive function, neuropsychological performance, young adults, adolescents, working memory, processing speed, sustained attention, interference control, verbal learning, learning and memory
MeSH terms
Adolescent, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Cognition, Female, Humans, Male, Neuropsychological Tests, Psychotropic Drugs, Severity of Illness Index, Case-Control Studies, Diagnostic and Statistical Manual of Mental Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review